Table 2.

Transplant procedures in patients with and without IBD.

	IBD N=49	No IBD N=96	P
Conditioning Regimen Intensity
Myeloablative	9 (18.4%)	28 (29.2%)	0.158
Reduced Toxicity/Reduced Intensity	40 (81.6%)	68 (70.8%)
Conditioning Regimen Serotherapy
Anti-Thymocyte Globulin	19 (38.8%)	40∧ (42.6%)	0.908
Alemtuzumab	26 (53.1%)	47∧ (50.0%)
None	4 (8.2%)	7A (7.4%)
Donor and Recipient Relation and HLA Match			0.689
Matched Sibling Donor	8 (16.3%)	22 (22.9%)
Matched Other Related Donor	4 (8.2%)	4 (4.2%)
Mismatched Related Donor&	2 (4.1%)	5 (5.2%)
Matched Unrelated Donor	29 (59.2%)	50 (52.1%)
Mismatched Unrelated Donor%	6 (12.2%)	15 (15.6%)
Graft Source			<0.001
Bone Marrow	20 (40.8%)	61 (63.5%)
Peripheral Blood Stem Cell	23 (46.9%)	15 (15.6%)
Cord Blood	6 (12.2%)	17 (17.7%)
Bone Marrow and Cord Blood	0	3 (3.1%)
Graft Manipulation to Achieve T-cell Depletion	0	2* (2.1%)	0.454
Acute GVHD Prophylaxis			0.003
Calcineurin Inhibitor +/− 1 or More Additional Agents	29 (59.2%)	79 (82.3%)
Other	20 (40.8%)	15 (15.6%)
None	0	2 (2.1%)

^∧Serotherapy was reported for 94 patients without IBD

^&Three patients received a 7/8 HLA matched graft, 1 patient received a 6/8 HLA matched graft, 1 patient received a 5/8 HLA matched graft, and 2 patients received haploidentical grafts

^%Two patients received a 4/6 HLA matched graft, 3 patients received a 5/8 HLA matched graft, 5 patients received a 6/8 HLA matched graft, 11 patients received a 7/8 HLA matched graft

^*Graft manipulation was reported for 95 patients without IBD